[Letter: Treatment of Zollinger-Ellison syndromes with metiamide or cimetidine. Potential risk of hyperimmunization manifestations].
D000917:Antibody Formation / Q000187:drug effects*; D006146:Guanidines / Q000009:adverse effects / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008785:Metiamide / Q000009:adverse effects / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects*; D013890:Thiourea / Q000031:analogs & derivatives*; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy*
D006146:Guanidines; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D008785:Metiamide; D013890:Thiourea
Traitement du syndrome de Zollinger-Ellison par la métiamide ou la cimétidine. Risque potentiel de manifestations d'hyperimmunisation